Finance Foggle

Vinay Prasad Exits FDA: Abrupt Resignation of CBER Director & Chief Medical Officer After 3 Months | Sarepta Gene Therapy Controversy, Political Pressure & Regulatory Impact Key Takeaways Abrupt Exit : Vinay Prasad resigned as FDA’s biologics chief after less than three months amid political pressure and drug approval controversies . Sarepta Controversy : His scrutiny of  Elevidys , a Duchenne muscular dystrophy therapy, led to shipment halts after a patient death, reversed days before his departure . Political Targeting : Right-wing activist  Laura Loomer  spearheaded a smear campaign, branding Prasad a “progressive saboteur” for past critiques of Trump and COVID policies . Scientific Clash : Prasad overruled FDA scientists on COVID vaccines, limiting boosters to high-risk groups, drawing ire from public health experts . The Resignation Heard ‘Round the Beltway Vinay Prasad quit on a Tuesday. The FDA’s biologics chief walked out after 89 days, a blip in bureaucra...

  Key Takeaways Sarepta Therapeutics stock plunged ~40% following a second patient death linked to its gene therapy Elevidys . FDA may pull Elevidys off the market as safety concerns mount; shipments halted for non-ambulatory patients . Therapy initially approved controversially in 2023 for ages 4-5, later expanded amid efficacy debates . Year-to-date stock loss exceeds 87%, erasing billions in market value . Duchenne muscular dystrophy patients face renewed uncertainty as treatment risks outweigh benefits for some . The Bloodbath on Nasdaq Sarepta Therapeutics stock cratered 40% in premarket trading June 16, 2025. It opened at $13.60, a far cry from its 52-week high of $150.48 . The collapse wasn't a surprise to those watching the ticker. Shares had been dying a slow death all year. By July, the year-to-date loss hit 87.5% . Shareholders stared at ruins. Trading volume exploded to 60 million shares. Average volume is 5.9 million . The market cap vaporized, $1.336 billion intraday....